Targeting the Genetic Root Cause: Atrium Therapeutics’ RNA Approach to Rare Cardiomyopathies
Date: August 19, 2026
Time: 6:00pm EDT
Join Atrium Therapeutics for an introduction to the company and its mission to pioneer targeted RNA delivery directly to the heart, transforming care for people living with rare, life-threatening genetic cardiomyopathies. Hear how Atrium’s lead programs — ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN cardiomyopathy — are designed to address the underlying genetic drivers of these conditions for the first time.
Presenters:
Dr. Husam Younis is Chief Scientific Officer at Atrium Therapeutics, with more than 20 years of experience in drug discovery and development, including in rare disease. He has held senior leadership roles in research and development science at Avidity Biosciences, NGM Biopharmaceuticals, Ionis Pharmaceuticals and Pfizer. His experience spans multiple drug modalities and therapeutic areas and he has led research and development teams to advance multiple programs from preclinical research to first-in-human studies and to BLA submission. Dr. Younis completed his graduate training in pharmacology and toxicology and pharmacy practice at the College of Pharmacy at the University of Arizona.
Sharon Paige, MD, PhD is a physician-scientist and pediatric cardiologist with deep expertise in cardiac genetics, cardiomyopathy, congenital heart disease, and stem cell biology. She currently is the Clinical Development lead for the PRKAG2 program at Atrium Therapeutics, where she helps advance innovative therapeutic approaches for patients with inherited cardiovascular disease. Dr. Paige has dedicated her career to bridging translational research and patient-centered care, with a strong commitment to improving outcomes for patients of all ages affected by rare and genetic heart conditions. She is passionate about collaborating with patient advocacy organizations to accelerate research, education, and access to emerging therapies.
Register Now